Dr. Emre Yekedüz is a medical oncologist and research fellow in medicine at Dana-Farber Cancer Institute in Boston.
What is on the Horizon for Kidney Cancer?
Dr. Emre Yekedüz discusses how ASCO 2025 highlights precision medicine, biomarkers and the gut microbiome as keys to advancing kidney cancer care.
Read More
Gene Variant May Predict Side Effects From Kidney Cancer Immunotherapy
A variant in the IL-7 gene may predict which patients with kidney cancer are more likely to experience side effects from immunotherapy.
Top 3 Takeaways From ASCO GU 2025
Dr. Emre Yekedüz discusses his top 3 key takeaways from attending the 2025 ASCO Genitourinary (GU) Cancers Symposium.
Investigating Quality of Life and Treatment Adherence in Kidney Cancer
Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side effects in renal cell carcinoma.